This reports provides a data-driven overview of the current and future competitive landscape in Sjogren's Syndrome therapeutics.
Key Highlights
- In 2022, there will be more than 3.9 million diagnosed prevalence cases of Sjogren's Syndrome across 16 pharmaceutical markets.
- No FDA-approved marketed drugs have been available for Sjogren's Syndrome in the last two decades.
- The Sjogren's Syndrome pipeline consists of 49 pharmaceuticals spanning all stages of development, with approximately 36% of drugs in mid- to late-stage development.
- Commercial sponsors dominate clinical trial development in Sjogren's Syndrome, with the US emerging as the key countries for conducting trials in Sjogren's Syndrome.
- Deals involving partnerships were the most common type of deals globally.
- Therapeutic options for Sjogren's Syndrome patients continue to be limited as only two new product approvals are expected within the next 5 years.
Scope
The publisher's Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type and Route of Administration
- Product Profiles with Sales Forecast
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Sjogren's Syndrome market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Sjogren's Syndrome market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1 Preface
3 Disease Landscape
5 Pipeline Drugs Assessment
6 Clinical Trials Assessment
7 Deals Landscape
8 Commercial Assessment
10 Appendix